ABATA
Filed on Dec 18, 2024
Pharmaceutical preparations for cell therapy, namely pharmaceutical preparations for T cell therapy; pharmaceutical preparations and vaccines for use in gene therapy and cell therapy; biological preparations for use in medical and clinical gene therapy and cell therapy for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; pharmaceutical products for the prevention and treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; immunotherapy products, namely, pharmaceutical preparations for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; biological preparations for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory disorders, transplant complications, and immunological disorders; chemical and biochemical preparations for medical purposes, specifically, for the treatment and diagnosis of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; biochemical, namely, monoclonal antibodies for medical purposes, specifically, for the treatment and diagnosis of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders
Abata Therapeutics, Inc.
100 Forge Road, Suite 200, Watertown, MASSACHUSETTS, UNITED STATES, 02472